Excellent results, setting up for excellent H2, takeoverDo not be fooled by the naysayers. This was an excellent quarter in view of the Pandemic challenges. Valens has one of the strongest balance sheets in the industry and is poised for significant growth over the next few years. My biggest concern is the company gets taken out by a lame offer in the $4 - $5 range before the true potential is realized. So many partnerships, so many irons in the fire, unique set of skill sets, Thermo Fisher seal of approval, etc. This company, having a rather small market cap and enterprise value is unfortunately a sitting duck to be taken over too cheaply. Smart shareholders, and hopefully the board, would refuse anything but a fair offer. This quarter's results in tough times more than demonstrate the company's ability to excel as the economy gradually reopens. Hold your shares tight and ignore BS comments from uninformed critics who don't know how to read and analyze a balance sheet, etc. In this environment, this was an excellent quarter!